May 2024

Frontera Therapeutics’s Quality Control for rAAV Gene Therapy Products Presented at the 23rd China Biological Products Annual Conference 2024

News /

May 16-18, 2024— the 23rd China Biological Products Annual Conference was held in Guangzhou, China. Dr. Li Aiqun, Director of QC, Frontera Therapeutics, was invited to participate in the symposium of “Immune Cells, Stem Cells and Gene Therapy” and focused on “Quality Control of rAAV Gene Therapy Products: Challenges of Next Generation Sequencing and Residual DNA […]

Frontera Therapeutics’s Quality Control for rAAV Gene Therapy Products Presented at the 23rd China Biological Products Annual Conference 2024 Read More »

Frontera Therapeutics Unveils Preliminary Clinical Results for FT-002 Injection at Retinal Cell and Gene Therapy Innovation Summit 2024

News /

May 6, 2024–Frontera Therapeutics is pleased to announce significant advancements in our clinical study of FT-002, presented at Retinal Cell and Gene Therapy Innovation Summitin the United States on May 3, 2024. Professor Sui Ruifang, from Peking Union Medical College Hospital, was invited to present the clinical results, titled “Preliminary safety and efficacy of an

Frontera Therapeutics Unveils Preliminary Clinical Results for FT-002 Injection at Retinal Cell and Gene Therapy Innovation Summit 2024 Read More »